The Mini-Case, “Pay-for-Delay Agreements” states that some incumbent producers of drugs with expiring patents paid potential generic producers to delay entry into the market. Why were incumbents willing to offer enough to potential entrants to make them delay entry? How will the 2013 Supreme Court decision allowing possible legal action against the companies affect this calculation?